November 9, 2023 06:36 AM ESTUpdated November 10, 11:34 AM
Pharma

Mer­ck KGaA’s Baven­cio no longer 'alone' in blad­der can­cer mar­ket, but growth op­por­tu­ni­ty re­mains

Ayisha Sharma

News Reporter

Mer­ck KGaA’s Baven­cio will face its first com­peti­tor in first-line blad­der can­cer in the form of Seagen and Astel­las’ Pad­cev plus Mer­ck’s Keytru­da, but the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times